| pubmed-article:7492381 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7492381 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7492381 | lifeskim:mentions | umls-concept:C0079460 | lld:lifeskim |
| pubmed-article:7492381 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:7492381 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:7492381 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:7492381 | lifeskim:mentions | umls-concept:C1328050 | lld:lifeskim |
| pubmed-article:7492381 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:7492381 | lifeskim:mentions | umls-concept:C0205488 | lld:lifeskim |
| pubmed-article:7492381 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:7492381 | pubmed:dateCreated | 1996-1-11 | lld:pubmed |
| pubmed-article:7492381 | pubmed:abstractText | Twenty patients with recurrent metastatic breast cancer treated with high-dose myelosuppressive antineoplastic drugs (cyclophosphamide 2.5 g/m2 or epirubicin 130 mg/m2, both every 3 weeks) as first or second line chemotherapy were randomized in a prospective study to GM-CSF 5 micrograms/kg per day (n = 11) or control (n = 9). Significant reduction in granulocyte nadir duration (2 days with GM-CSF vs. 7 days) and severity (0.4 x 10(9)/l with GM-CSF vs. 0.2 x 10(9)/l) was found. No difference in frequency of neutropenic fever or antibiotic use could be observed. Even though the patients treated with GM-CSF at random were more heavily pretreated with chemotherapy, there was a surprisingly higher response rate in these patients as compared to the control-arm, namely 64% vs. 28.5%. However, this difference was not statistically significant. No severe side-effects were seen, but presumably due to GM-CSF one patient developed an allergic type 1 reaction and one patient a possible pericardial exudation. Both were fully reversible after cessation of the cytokine treatment. | lld:pubmed |
| pubmed-article:7492381 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7492381 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7492381 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7492381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7492381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7492381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7492381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7492381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7492381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7492381 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7492381 | pubmed:issn | 0284-186X | lld:pubmed |
| pubmed-article:7492381 | pubmed:author | pubmed-author:SkovsgaardTT | lld:pubmed |
| pubmed-article:7492381 | pubmed:author | pubmed-author:HansenFF | lld:pubmed |
| pubmed-article:7492381 | pubmed:author | pubmed-author:StenbygaardLL | lld:pubmed |
| pubmed-article:7492381 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7492381 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:7492381 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7492381 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7492381 | pubmed:pagination | 919-24 | lld:pubmed |
| pubmed-article:7492381 | pubmed:dateRevised | 2009-5-12 | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:meshHeading | pubmed-meshheading:7492381-... | lld:pubmed |
| pubmed-article:7492381 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7492381 | pubmed:articleTitle | Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hematologic toxicity induced by high-dose chemotherapy in patients with metastatic breast cancer. | lld:pubmed |
| pubmed-article:7492381 | pubmed:affiliation | Department of Oncology, Herlev University Hospital, Denmark. | lld:pubmed |
| pubmed-article:7492381 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7492381 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7492381 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
